132 related articles for article (PubMed ID: 17846944)
1. [Persistent corneal defects treated with botulinum toxin-induced ptosis].
Vleming EN; Pérez-Rico C; Montes MA; Pareja J
Arch Soc Esp Oftalmol; 2007 Sep; 82(9):547-50. PubMed ID: 17846944
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis.
Ellis MF; Daniell M
Clin Exp Ophthalmol; 2001 Dec; 29(6):394-9. PubMed ID: 11778810
[TBL] [Abstract][Full Text] [Related]
3. Rate of epithelialisation and re-operations in corneal ulcers treated with amniotic membrane transplantation combined with botulinum toxin-induced ptosis.
Fuchsluger T; Tuerkeli E; Westekemper H; Esser J; Steuhl KP; Meller D
Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):955-64. PubMed ID: 17219124
[TBL] [Abstract][Full Text] [Related]
4. [Botulinum toxin injection for production of ptosis].
Merté RL; Lanzl IM
Ophthalmologe; 2007 Sep; 104(9):767-70. PubMed ID: 17846779
[TBL] [Abstract][Full Text] [Related]
5. Anterior chemodenervation of levator palpebrae superioris with botulinum toxin type-A (Botox) to induce temporary ptosis for corneal protection.
Naik MN; Gangopadhyay N; Fernandes M; Murthy R; Honavar SG
Eye (Lond); 2008 Sep; 22(9):1132-6. PubMed ID: 17510652
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin-A-induced protective ptosis in the treatment of lagophthalmos associated with facial paralysis.
Yücel OE; Artürk N
Ophthalmic Plast Reconstr Surg; 2012; 28(4):256-60. PubMed ID: 22785583
[TBL] [Abstract][Full Text] [Related]
7. [Protective ptosis by botulinum A toxin injection in corneal affectations].
Gusek-Schneider GC; Erbguth F
Klin Monbl Augenheilkd; 1998 Jul; 213(1):15-22. PubMed ID: 9743934
[TBL] [Abstract][Full Text] [Related]
8. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
Cardoso F
Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
[TBL] [Abstract][Full Text] [Related]
9. Duration of botulinum toxin effect in the treatment of crocodile tears.
Nava-Castañeda A; Tovilla-Canales JL; Boullosa V; Tovilla-y-Pomar JL; Monroy-Serrano MH; Tapia-Guerra V; Garfias Y
Ophthalmic Plast Reconstr Surg; 2006; 22(6):453-6. PubMed ID: 17117101
[TBL] [Abstract][Full Text] [Related]
10. A modified transconjunctival technique for botulinum toxin chemodenervation of levator palpebrae superioris for corneal protection.
Tint NL; Saxby EPI; Young SL; Alexander P
Eye (Lond); 2022 Jun; 36(6):1217-1221. PubMed ID: 34117397
[TBL] [Abstract][Full Text] [Related]
11. Ptosis as a remote effect of therapeutic botulinum toxin B injection.
Racette BA; Lopate G; Good L; Sagitto S; Perlmutter JS
Neurology; 2002 Nov; 59(9):1445-7. PubMed ID: 12427903
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
Dessy LA; Fallico N; Mazzocchi M; Scuderi N
Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based approach of the use of Botulinum toxin type A (BTX) in cerebral palsy.
Wong V
Pediatr Rehabil; 2003; 6(2):85-96. PubMed ID: 14534045
[TBL] [Abstract][Full Text] [Related]
15. Persistence of Upper Blepharoptosis After Cosmetic Botulinum Toxin Type A.
Steinsapir KD; Groth MJ; Boxrud CA
Dermatol Surg; 2015 Jul; 41(7):833-40. PubMed ID: 26057409
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin injections for chronic sialorrhoea in children are effective regardless of the degree of neurological dysfunction: A single tertiary institution experience.
Mahadevan M; Gruber M; Bilish D; Edwards K; Davies-Payne D; van der Meer G
Int J Pediatr Otorhinolaryngol; 2016 Sep; 88():142-5. PubMed ID: 27497402
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department.
Tomić A; Vujović B; Svetel M; Misković ND; Petrović I; Pekmezović T; Kostić VS
Vojnosanit Pregl; 2015 Dec; 72(12):1069-73. PubMed ID: 26898029
[TBL] [Abstract][Full Text] [Related]
18. The adjunctive usage of botulinum toxin.
Carruthers J; Carruthers A
Dermatol Surg; 1998 Nov; 24(11):1244-7. PubMed ID: 9834746
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.
Defazio G; Abbruzzese G; Girlanda P; Vacca L; Currà A; De Salvia R; Marchese R; Raineri R; Roselli F; Livrea P; Berardelli A
Arch Neurol; 2002 Mar; 59(3):418-20. PubMed ID: 11890846
[TBL] [Abstract][Full Text] [Related]
20. A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: a retrospective, open-label chart review.
Lang AM
Clin Ther; 2003 Aug; 25(8):2268-78. PubMed ID: 14512133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
